The U.S. Food and Drug Administration has cleared BTL’s Emsculpt Neo for use in stimulating neuromuscular tissue for bulk muscle excitation in the legs or arms for rehabilitative purposes.
Emsculpt Neo is now cleared for:
- Prevention or retardation of disuse atrophy
- Muscle re-education
- Maintaining or increasing range of motion
- Immediate post-surgical prevention of calf muscles to prevent venous thrombosis
- Relaxation of muscle spasms
- Increasing local blood circulation
“This FDA clearance opens up new frontiers and possibilities for Emsculpt Neo as a platform that continues to evolve, bringing new patients to practices,” says Rohit Mishra, BTL’s Director of Product Management, in a news release. “We are committed to innovation that meets the changing needs of our customers, and this advancement reinforces our dedication to excellence in both the aesthetic and medical fields.”
